-
公开(公告)号：US07772373B2
公开(公告)日：2010-08-10
申请号：US11867775
申请日：2007-10-05
IPC分类号： C07K16/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
摘要翻译： 本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。
-
公开(公告)号：US20100136626A1
公开(公告)日：2010-06-03
申请号：US12582009
申请日：2009-10-20
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
-
43.发明授权Production and use of novel peptide-based agents for use with bi-specific antibodies 有权用于双特异性抗体的新型基于肽的试剂的生产和使用公开(公告)号：US07563439B2
公开(公告)日：2009-07-21
申请号：US11923279
申请日：2007-10-24
IPC分类号： A61K39/395 , C07K16/30 , C07K16/44
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. In one embodiment, the invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
摘要翻译： 本发明涉及一种双特异性抗体或抗体片段，其具有至少一个对靶组织有反应性的臂，以及至少一个对接头部分具有反应性的其它臂。 接头部分包括已经制备抗体的半抗原。 在优选的实施方案中，半抗原是组胺 - 琥珀酰甘氨酸（HSG）。 在更优选的实施方案中，所述至少一个臂包含HSG结合679抗体的CDR序列。 抗原性接头与一种或多种治疗剂或诊断剂或酶缀合。 在一个实施方案中，本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。
-
公开(公告)号：US07501498B2
公开(公告)日：2009-03-10
申请号：US11870627
申请日：2007-10-11
IPC分类号： C07K16/00 , C12P21/08 , C12P21/04 , A61K39/395 , C07H21/04
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6843 , A61K49/0002 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/24 , C07K2317/56 , G01N33/57484 , G01N33/689
摘要： The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
摘要翻译： 本发明提供人源化，嵌合和人抗甲胎蛋白抗体，融合蛋白及其片段。 抗体，融合蛋白及其片段以及与其它合适抗体的组合可用于治疗和诊断肝细胞癌，肝母细胞瘤，生殖细胞肿瘤癌和其他产生AFP的肿瘤。
-
公开(公告)号：US08337840B2
公开(公告)日：2012-12-25
申请号：US13398214
申请日：2012-02-16
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/2803 , A61K38/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1069 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/2809 , C07K16/283 , C07K16/2833 , C07K16/2887 , C07K16/30 , C07K16/3061 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/92
摘要： The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.
-
公开(公告)号：US20120232132A1
公开(公告)日：2012-09-13
申请号：US13384163
申请日：2010-01-15
申请人： Yixian Zhang , Zhengxing Qu
发明人： Yixian Zhang , Zhengxing Qu
IPC分类号： A61K31/711 , A61P35/02
CPC分类号： A61K31/7088
摘要： The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.
摘要翻译： 本发明涉及用于治疗和预防靶细胞中GLI2 mRNA的急性骨髓性白血病的低聚物化合物（低聚物），导致GLI2的表达降低。
-
公开(公告)号：US08188239B2
公开(公告)日：2012-05-29
申请号：US13089645
申请日：2011-04-19
申请人： Hans J. Hansen , William J. McBride , Zhengxing Qu
发明人： Hans J. Hansen , William J. McBride , Zhengxing Qu
IPC分类号： C07K17/00
CPC分类号： C07K16/2887 , A61K47/6897 , A61K51/1027 , A61K51/1048 , A61K51/109 , A61K2039/505 , B82Y5/00 , C07K16/3007 , C07K2317/31 , C07K2317/622 , C07K2319/00 , C07K2319/01
摘要： Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.
摘要翻译： 本文提供作为双特异性抗体的多价载体的可靶向构建体，即可靶向构建体的每个分子可以用作两种或更多种双特异性抗体的载体。 还提供了通过可靶向构建体与两种或更多种双特异性抗体缔合形成的可靶向复合物。 将本发明的可靶向构建体和可靶向复合物掺入生物传感器，试剂盒和药物组合物中，并且以多种治疗和其它方法使用。
-
公开(公告)号：US07951921B2
公开(公告)日：2011-05-31
申请号：US12436352
申请日：2009-05-06
申请人： Hans J. Hansen , William J. McBride , Zhengxing Qu
发明人： Hans J. Hansen , William J. McBride , Zhengxing Qu
IPC分类号： C07K17/00
CPC分类号： C07K16/2887 , A61K47/6897 , A61K51/1027 , A61K51/1048 , A61K51/109 , A61K2039/505 , B82Y5/00 , C07K16/3007 , C07K2317/31 , C07K2317/622 , C07K2319/00 , C07K2319/01
摘要： Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.
摘要翻译： 本文提供作为双特异性抗体的多价载体的可靶向构建体，即可靶向构建体的每个分子可以用作两种或更多种双特异性抗体的载体。 还提供了通过可靶向构建体与两种或更多种双特异性抗体缔合形成的可靶向复合物。 将本发明的可靶向构建体和可靶向复合物掺入生物传感器，试剂盒和药物组合物中，并且以多种治疗和其它方法使用。
-
49.发明申请Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof 有权α-甲胎蛋白Immu31抗体和融合蛋白及其使用方法公开(公告)号：US20100196989A1
公开(公告)日：2010-08-05
申请号：US12359745
申请日：2009-01-26
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6843 , A61K49/0002 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/24 , C07K2317/56 , G01N33/57484 , G01N33/689
摘要： The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
摘要翻译： 本发明提供人源化，嵌合和人抗甲胎蛋白抗体，融合蛋白及其片段。 抗体，融合蛋白及其片段以及与其它合适抗体的组合可用于治疗和诊断肝细胞癌，肝母细胞瘤，生殖细胞肿瘤癌和其他产生AFP的肿瘤。
-
50.发明申请Mammalian Cell Lines for Increasing Longevity and Protein Yield from a Cell Culture 有权哺乳动物细胞系从细胞培养增加寿命和蛋白质产量公开(公告)号：US20090253179A1
公开(公告)日：2009-10-08
申请号：US12405733
申请日：2009-03-17
申请人： David M. Goldenberg , Zhengxing Qu , Chien-Hsing Chang , Edmund A. Rossi , Jeng-Dar Yang , Diane Nordstrom
发明人： David M. Goldenberg , Zhengxing Qu , Chien-Hsing Chang , Edmund A. Rossi , Jeng-Dar Yang , Diane Nordstrom
CPC分类号： C07K16/2896 , A61K2039/505 , C07K14/005 , C07K14/4747 , C07K16/00 , C07K16/18 , C07K16/2803 , C07K16/3007 , C07K2317/24 , C07K2317/31 , C12N5/0694 , C12N15/85 , C12N15/86 , C12N2500/90 , C12N2501/48 , C12N2510/02 , C12N2710/20022 , C12N2740/10043 , C12P21/02
摘要： Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.
摘要翻译： 公开了用于增加细胞培养物的寿命并允许增加蛋白质生产的组合物和方法，优选重组蛋白，例如抗体，肽，酶，生长因子，白细胞介素，干扰素，激素和疫苗。 用凋亡抑制基因或载体如三重突变体Bcl-2基因转染的细胞可以在培养物中更长时间地存活，导致蛋白质生物合成的状态和产量的延长。 这样的转染细胞表现出最大的细胞密度，其等于或超过由亲本细胞系实现的最大密度。 转染的细胞也可以预先适应于无血清培养基中生长，大大减少了在无血清培养基中获得蛋白质产生所需的时间。 在某些方法中，预先调节的细胞可以在无血清条件下转化后用于蛋白质生产。 该方法优选涉及真核细胞，更优选哺乳动物细胞。
-
-
-
-
-
-
-
-
-
搜索结果
94 条记录 (耗时 0.044 秒)
